References

Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to destruction

10.1038/s41584-018-0070-0 · 2018 · External reference

Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis

10.1038/s41584-024-01154-0 · 2024 · External reference

2023 American College of Rheumatology/American College of Chest Physicians guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases

10.1002/acr.25347 · 2024 · External reference

2023 American College of Rheumatology/American College of Chest Physicians guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases

10.1002/acr.25348 · 2024 · External reference

ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease

10.1183/13993003.02533-2024 · 2026 · External reference

Interstitial lung disease diagnosis and prognosis using an AI system integrating longitudinal data

10.1038/s41467-023-37720-5 · 2023 · External reference

Deep learning for classifying fibrotic lung disease on high-resolution computed tomography: a case-cohort study

10.1016/s2213-2600(18)30286-8 · 2018 · External reference

Deep learning-based outcome prediction in progressive fibrotic lung disease using high-resolution computed tomography

10.1164/rccm.202112-2684oc · 2022 · External reference

Prognostic value of automated assessment of interstitial lung disease on CT in systemic sclerosis

10.1093/rheumatology/kead164 · 2024 · External reference

Machine learning of plasma proteomics classifies diagnosis of interstitial lung disease

10.1164/rccm.202309-1692oc · 2024 · External reference

A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis

10.1002/art.20553 · 2004 · External reference

A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope) - restricted immune reactions to autoantigens modified by citrullination

10.1002/art.21575 · 2006 · External reference

Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease

10.1002/art.38066 · 2013 · External reference

Anti-citrullinated protein antibodies are associated with neutrophil extracellular traps in the sputum in relatives of rheumatoid arthritis patients

10.1002/art.40066 · 2017 · External reference

Association of sputum neutrophil extracellular trap subsets with IgA anti-citrullinated protein antibodies in subjects at risk for rheumatoid arthritis

10.1002/art.41948 · 2022 · External reference

Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease

10.1016/j.rmed.2012.03.006 · 2012 · External reference

Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis

10.1002/art.38201 · 2014 · External reference

10.1172/jci28756

10.1172/jci28756 · External reference

The lung may play a role in the pathogenesis of rheumatoid arthritis

10.2217/ijr.14.23 · 2014 · External reference

Neutrophil extracellular traps kill bacteria

10.1126/science.1092385 · 2004 · External reference

NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis

10.1126/scitranslmed.3005580 · 2013 · External reference

Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage

10.1073/pnas.1114465108 · 2011 · External reference

Identification and management of interstitial lung disease associated with systemic sclerosis (SSc-ILD), rheumatoid arthritis (RA-ILD), and polymyositis/dermatomyositis (PM/DM-ILD): development of expert consensus-based clinical algorithms

10.1080/17476348.2024.2374910 · 2024 · External reference

The diagnostic utility of lung ultrasound in the assessment of interstitial lung disease associated with rheumatoid arthritis

10.1186/s13075-025-03626-4 · 2025 · External reference

Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial

10.1016/s0140-6736(23)02649-1 · 2024 · External reference

Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial

10.1016/s0140-6736(23)02650-8 · 2024 · External reference

Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study

10.1136/annrheumdis-2017-212763 · 2019 · External reference

A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis

10.1002/art.43366 · 2026 · External reference

High-resolution CT findings in interstitial lung disease associated with connective tissue diseases: differentiating patterns for clinical practice-a systematic review with meta-analysis

10.3390/jcm14176164 · 2025 · External reference

10.1080/03009742.2025.2538946

10.1080/03009742.2025.2538946 · External reference

MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease

10.1056/nejmoa1801562 · 2018 · External reference

Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline

10.1164/rccm.202202-0399st · 2022 · External reference

RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease

10.1002/art.24621 · 2009 · External reference

Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis

10.1093/rheumatology/keq149 · 2010 · External reference

10.1002/art.41105

10.1002/art.41105 · 2020 · External reference

Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model

2024 · External reference

Development of a machine learning model in prediction of the rapid progression of interstitial lung disease in patients with idiopathic inflammatory myopathy

10.21037/qims-24-595 · 2024 · External reference

Pulmonary manifestations of Sjögren’s syndrome

10.1183/16000617.0011-2016 · 2016 · External reference

Interstitial lung disease in primary Sjögren’s syndrome

10.1186/s12890-022-01868-5 · 2022 · External reference

Quantitative assessment of interstitial lung disease in Sjögren’s syndrome

10.1371/journal.pone.0224772 · 2019 · External reference

Systematic review of diffuse alveolar hemorrhage in systemic lupus erythematosus: focus on outcome and therapy

10.1097/rhu.0000000000000291 · 2015 · External reference

EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update

10.1136/ard-2022-223764 · 2024 · External reference

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

10.1056/nejmoa0909905 · 2010 · External reference

Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis

10.1056/nejmoa1803537 · 2020 · External reference

Expert perspectives: defining and managing progressive pulmonary fibrosis in systemic sclerosis

10.1002/art.70237 · 2026 · External reference

Combined immunosuppressive therapy in systemic sclerosis-associated interstitial lung disease: phenotypes matter

10.1016/j.autrev.2026.104092 · 2026 · External reference

Cyclophosphamide versus placebo in scleroderma lung disease

10.1056/nejmoa055120 · 2006 · External reference

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (scleroderma lung study II): a randomised controlled, double-blind, parallel group trial

10.1016/s2213-2600(16)30152-7 · 2016 · External reference

Nintedanib for systemic sclerosis-associated interstitial lung disease

10.1056/nejmoa1903076 · 2019 · External reference

Nintedanib in progressive fibrosing interstitial lung diseases

10.1056/nejmoa1908681 · 2019 · External reference

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): a randomised, double-blind, double-dummy, phase 2b trial

10.1016/s2213-2600(22)00359-9 · 2023 · External reference

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

10.1016/s2213-2600(20)30318-0 · 2020 · External reference

Autoimmune pulmonary alveolar proteinosis

10.1055/a-2737-7719 · 2026 · External reference

Environment, lifestyles, and climate change: the many nongenetic contributors to the long and winding road to autoimmune diseases

10.1002/acr.25423 · 2025 · External reference

Amphibole asbestos as an environmental trigger for systemic autoimmune diseases

2024 · External reference

Exposome: epigenetics and autoimmune diseases

10.1016/j.autrev.2024.103584 · 2024 · External reference

The role of microbiota and oxidative stress axis and the impact of intravenous immunoglobulin in systemic lupus erythematosus

10.1016/j.autrev.2024.103607 · 2024 · External reference

Oxidative stress, mitochondrial dysfunction, and respiratory chain enzyme defects in inflammatory myopathies

10.1016/j.autrev.2023.103308 · 2023 · External reference

Piezo1 in respiratory diseases: mechanotransduction, cell-specific functions, and translational implications

2026 · External reference

Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease

10.1136/annrheumdis-2018-214865 · 2019 · External reference

Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease

10.1136/annrheumdis-2021-220493 · 2022 · External reference

Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis

10.1164/rccm.201712-2410oc · 2019 · External reference

An integrated cell atlas of the lung in health and disease

10.1038/s41591-023-02327-2 · 2023 · External reference

Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis

10.1126/sciadv.aba1983 · 2020 · External reference

Spatial multiomics decipher fibroblast-macrophage dynamics in systemic sclerosis

10.1016/j.ard.2025.04.025 · 2025 · External reference

Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications

10.1038/s41467-022-34145-4 · 2022 · External reference

Panel of serum biomarkers for differential diagnosis of idiopathic interstitial lung disease and interstitial lung disease-secondary to systemic autoimmune rheumatic disease

10.1371/journal.pone.0311357 · 2024 · External reference

Intravenous immunoglobulin as a therapy for autoimmune conditions

10.1016/j.autrev.2024.103710 · 2025 · External reference

A machine learning analysis to evaluate the outcome measures in inflammatory myopathies

10.1016/j.autrev.2023.103353 · 2023 · External reference

A machine learning analysis to predict the response to intravenous and subcutaneous immunoglobulin in inflammatory myopathies. A proposal for a future multi-omics approach in autoimmune diseases

10.1016/j.autrev.2022.103105 · 2022 · External reference

Integrating clinical data and medical imaging in lung Cancer: feasibility study using the observational medical outcomes partnership common data model extension

10.2196/59187 · 2024 · External reference

Computational approaches to multimodal data integration in rheumatoid arthritis: from data landscape to clinical translation

10.1093/bib/bbag073 · 2026 · External reference

TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods

10.1136/bmj-2023-078378 · 2024 · External reference

Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension

10.1038/s41591-020-1034-x · 2020 · External reference

Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension

10.1016/s2589-7500(20)30219-3 · 2020 · External reference

Reporting guideline for the early stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI

2022 · External reference

PROBAST: a tool to assess the risk of bias and applicability of prediction model studies

10.7326/m18-1376 · 2019 · External reference

PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration

10.7326/m18-1377 · 2019 · External reference

Checklist for artificial intelligence in medical imaging (CLAIM): a guide for authors and reviewers

10.1148/ryai.2020200029 · 2020 · External reference

FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare

10.1136/bmj-2024-081554 · 2025 · External reference

Ethical, legal, and social issues (ELSI) and reporting guidelines of AI research in healthcare

10.1371/journal.pdig.0000607 · 2024 · External reference